
    
      This study will evaluate the effects of cenicriviroc mesylate (CVC) on arterial inflammation
      in people living with HIV.

      Participants will be randomized to either the CVC arm (Arm A) or placebo for CVC arm (Arm B).
      CVC 150 mg or placebo for CVC will be added to the participants' pre-existing antiretroviral
      (ARV) regimens once a day for at least 24 weeks. For participants who are on an efavirenz
      (EFV)-based regimen, dosing will be 300 mg once a day.

      Study participants will remain on study treatment for approximately 24 weeks. Study visits
      may include blood collection, physical examinations, and FDG-PET/CT imaging.
    
  